Morphine Syringes Recalled Due to Sterility Assurance Failure
Central Admixture Pharmacy Services is recalling 1,699 morphine syringes nationwide due to lack of validated sanitization cycles, which may compromise sterility assurance.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II pharmaceutical recall of a sterile injection product with unvalidated sterilization processes, creating risk of harm. No illnesses or injuries have been reported, placing this at score 3 per the rubric for risk-of-harm products without reported injury.
Plain-English summary
Central Admixture Pharmacy Services Inc is recalling morphine 1 mg/mL in 0.9% sodium chloride 3 mL syringes (NDC 71286-2040-1) distributed nationwide. The recall affects 1,699 syringes across six lots.
The recall was initiated because the manufacturer lacked adequate validation data for the sanitization cycles used in manufacturing. This creates a lack of assurance that the syringes meet required sterility standards. Sterile pharmaceutical injections manufactured without validated sterilization processes may not be safe for patient use.
Affected lot numbers and expiration dates are: 17-270804 (Exp. 7/19/2023), 17-271108 (Exp. 7/25/2023), 17-271496 (Exp. 7/31/2023), 17-271844 (Exp. 8/6/2023), 17-272045 (Exp. 8/9/2023), and 17-272288 (Exp. 8/14/2023).
Patients and healthcare providers who have this product should contact Central Admixture Pharmacy Services Inc or their healthcare provider for guidance on proper handling and next steps.
The recalled product
- Product
- morphine in 0.9% sodium chloride, 1 mg/1 mL, (1 mg/mL), 3 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2040-1
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Category
- Drug — Injectable Medication
- Affected units
- 1,699
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (12)
- Lot: 17-270804
- Exp. 7/19/2023
- 17-271108
- Exp. 7/25/2023
- 17-271496
- Exp. 7/31/2023
- 17-271844
- Exp. 8/6/2023
- 17-272045
- Exp. 8/9/2023
- 17-272288
- Exp. 8/14/2023.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 39 recalled by Central Admixture Pharmacy Services Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 39 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services Inc
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighMidazolam Injectable Solution Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2023-10-11
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15